See related article by Toms *et al.*, <http://arthritis-research.com/content/11/4/R110> and related letter by Toms *et al.*, <http://arthritis-research.com/content/11/5/414>

With great interest, we read the article by Toms and colleagues \[[@B1]\] in the previous issue of *Arthritis Research & Therapy*, in which they assessed prevalences of metabolic syndrome (MetS) in rheumatoid arthritis (RA) patients. Moreover, they identified demographic and clinical factors that may be associated with MetS. Toms and colleagues found prevalences of up to 45% of MetS and demonstrated older age and health status (health assessment questionnaire) to be associated with MetS irrespectively of the definition used. Of most interest, an association between methotrexate (MTX) use and decreased presence of MetS was observed in patients more than 60 years of age. The investigators hypothesized that this may be attributed to a drug-specific effect (and not to an anti-inflammatory effect) either by changing levels of adenosine, which is known to interact with glucose and lipid metabolism, or by an indirect effect mediated through concomitant folic acid administration, thereby decreasing homocysteine levels.

Recently, we also examined the prevalence of MetS in (a subgroup of) RA patients in the CARRÉ investigation, a prospective cohort study on prevalent and incident cardiovascular disease and its underlying cardiovascular risk factors \[[@B2]\]. The findings of Toms and colleagues stimulated us to perform additional analyses in our total study population (n = 353).

The prevalences of MetS were 35% and 25% (Table [1](#T1){ref-type="table"}) according to criteria of National Cholesterol Education Program (NCEP) 2004 and NCEP 2001, respectively. In multivariate backward regression analyses, we found significant associations between body mass index, pulse rate, creatinine levels, hypothyroidism and diabetes mellitus and the presence of MetS independently of the criteria used (Table [2](#T2){ref-type="table"}). However, an independent association between single use of MTX or use of MTX in combination with other disease-modifying antirheumatic drugs, on the one hand, and a decreased prevalence of MetS, on the other hand, could not be demonstrated (even in the subgroup of patients over the age of 60).

###### 

Characteristics of the study population

                                       MetS present^a^   MetS absent^a^   MetS present^b^   MetS absent^b^              
  ------------------------------------ ----------------- ---------------- ----------------- ---------------- ---------- ----------
  Demographics                                                                                                          
   Age, years                          63.8 (± 8)        63.1 (± 7)       64.3 (± 8)        62.7 (± 7)       0.46       0.045
   Female, percentage                  76                63               74                62               0.022      0.028
  RA-related characteristics                                                                                            
   DAS28                               4.2 (± 1.3)       3.9 (± 1.4)      4.1 (± 1.3)       3.8 (± 1.4)      0.21       0.062
   ESR, mm/hour                        22 (10-35)        16 (9-30)        20 (10-34)        17 (9-31)        0.059      0.33
   CRP, mg/L                           11 (4-21)         6 (3-16)         8 (3-18)          6 (3-19)         0.021      0.46
   RA duration, years                  7 (4-10)          7 (4-10)         7 (4-10)          7 (5-10)         0.83       0.19
   Erosion, percentage                 77                83               79                83               0.20       0.36
   Number of DMARDs                    1 (1-2)           1 (1-1)          1 (1-2)           1 (1-1)          0.26       0.43
   MTX current, percentage             62                60               63                59               0.71       0.46
   MTX only, percentage                39                39               41                38               0.95       0.67
   SSZ only, percentage                8                 13               9                 14               0.23       0.22
   HCQ only, percentage                1                 4                3                 4                0.31       0.55
   Combination of DMARDs, percentage   31                25               29                25               0.24       0.38
   TNF-blocking agent, percentage      11                9                11                9                0.73       0.65
   Prednisolone only, percentage       1                 2                3                 1                1.00       0.42
  Cardiovascular risk factors                                                                                           
   Current smoker, percentage          26                31               25                32               0.42       0.15
   Pack-years, years                   17 (0-34)         19 (2-38)        19 (0-35)         18 (2-38)        0.23       0.75
   BMI, kg/m^2^                        30 (± 4)          26 (± 5)         29 (± 4)          25 (± 5)         \< 0.001   \< 0.001
   Creatinine, μmol/L                  89 (± 21)         89 (± 16)        91 (± 22)         87 (± 14)        0.99       0.070
   Renal clearance, mL/minute          81 (± 24)         72 (± 19)        77 (± 23)         73 (± 19)        0.003      0.062
   Pulse, beats per minute             76 (± 11)         73 (± 9)         75 (± 11)         73 (± 9)         0.005      0.015
   Diabetes mellitus, percentage       14                3                12                3                \< 0.001   0.001
   Hypothyroidism, percentage          12                2                9                 2                0.001      0.003

^a^Metabolic syndrome (MetS) according to National Cholesterol Education Program (NCEP) 2001; ^b^MetS according to NCEP 2004. Continuous variables are presented as means (± standard deviations) in cases of normal distribution or as medians (interquartile ranges) in cases of non-normal distribution. BMI, body mass index; CRP, C-reactive protein; DAS28, disease activity score using 28 joint counts; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HCQ, hydroxychloroquine; MTX, methotrexate; RA, rheumatoid arthritis; SSZ, sulfasalazine; TNF, tumour necrosis factor.

###### 

Variables associated with metabolic syndrome

                      Univariate   Multivariate^a^                                 
  ------------------- ------------ ----------------- ---------- ------ ----------- ----------
  Body mass index     1.2          1.1-1.3           \< 0.001   1.2    1.1-1.3     \< 0.001
  Pulse               1.03         1.01-1.06         0.011      1.03   1.00-1.06   0.020
  Creatinine          1.01         1.00-1.02         0.080      1.02   1.00-1.03   0.017
  Hypothyroidism      4.5          1.5-13.2          0.007      4.7    1.5-15.0    0.009
  Diabetes mellitus   4.8          1.8-12.9          0.002      4.5    1.4-15.2    0.014

^a^In multivariate analyses, the following variables were used: gender, age, prednisolone only, methotrexate only, sulfasalazine only, hydroxychloroquine only, tumour necrosis factor-blocking agents, combination of disease-modifying antirheumatic drugs, pack-years, smoking, erosions, DAS28 (disease activity score using 28 joint counts), body mass index, pulse rate, creatinine levels, renal clearance, hypothyroidism and diabetes mellitus. CI, confidence interval; OR, odds ratio.

Therefore, to get more support for a drug-specific effect, it is of interest to know whether or not in the study of Toms and colleagues the MTX effect was present only in the group of RA patients with single use of MTX or in the group of MTX-treated patients with other antirheumatic drugs. As patients with MetS were significantly older, it would give further information whether age was an independent risk factor for MetS in regression analyses. Moreover, as readers, we are not informed about comorbidities like diabetes and clinical hypothyroidism, which are notorious cardiometabolic risk factors. On the whole, we could not confirm a plausible protective role for the use of MTX and presence of MetS, and hence further investigation is required to explain the discrepancy between our findings and those of Toms and colleagues.

Abbreviations
=============

MetS: metabolic syndrome; MTX: methotrexate; NCEP: National Cholesterol Education Program; RA: rheumatoid arthritis.

Competing interests
===================

The authors declare that they have no competing interests.
